Business Context and Reporting Period
Quince Therapeutics, Inc. (QNCX) filed this Form 8-K on December 13, 2022, regarding a notice received from The Nasdaq Stock Market. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The Company received written notice from Nasdaq that it no longer complies with the minimum bid price requirement for continued listing. Specifically, the closing bid price of the Common Stock was below $1.00 per share for the last 30 consecutive trading days prior to December 13, 2022.
Guidance, Outlook, and Risks
- Compliance Period: The Company has been granted an initial 180-calendar-day compliance period to regain compliance, ending on June 12, 2023.
- Requirements to Cure: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive trading days prior to the deadline.
- Extension Options: If the Company fails to regain compliance by June 12, 2023, it may be eligible for an additional 180-day period if it elects to transfer to The Nasdaq Capital Market and meets specific market value and listing standards.
- Risk of Delisting: If the Company fails to regain compliance within the initial or any extended periods, the Common Stock will be subject to delisting.
- Management Commentary: The Company intends to monitor the stock price and consider available options to resolve the noncompliance, though there is no assurance that compliance will be achieved or that further extensions will be granted.
Investor Verification Checklist
- Verify the current closing bid price of QNCX common stock to assess progress toward the $1.00 threshold.
- Monitor the Company's stock price for 10 consecutive trading days to determine if the cure requirement is met before June 12, 2023.
- Review future filings for any announcements regarding a potential transfer to The Nasdaq Capital Market.
- Check for any subsequent notices from Nasdaq regarding the status of the compliance period or potential delisting.